A Danish cohort of patients being treated with fingolimod for relapsing-remitting multiple sclerosis showed high levels of treatment adherence, motivation, satisfaction, and quality of life, according to a study published in Patient Preference and Adherence.
This open-label, multicenter, 24-month study sought to investigate fingolimod treatment adherence, as well as resulting quality of life, motivation, and satisfaction. To avoid misinterpreting factors such as low tolerance and lack of treatment adherence, all 195 patients recruited for the study between October 2013 and April 2014 had been treated with fingolimod for at least 6 months prior.
To evaluate the effect of motivational interview support on treatment adherence, the study began with a 12-month observational phase, followed by a 12-month motivational interview phase after health care providers were given a 2-day course on motivational interviewing. Treatment adherence, satisfaction, motivation, and quality of life were assessed every 6 months.
Patients showed very high levels of treatment adherence throughout the study, as well as high TSQM-9 satisfaction scores, particularly in the convenience domain (94.51 to 95.78).
No statistically significant difference was found for adherence observed before and after clinicians initiated motivational interviewing (99% vs 97%; -0.0196 [-0.0453 to 0.0061] 95% CI, P =.1329).
The fact that the Danish health care providers involved in the study scored high on motivational interviewing skills even before training likely contributed to the lack of significant effect of training on adherence.
The patients in the study also appear to have a high degree of treatment support to help them cope with their multiple sclerosis, which likely contributed to high adherence levels as well.
Study investigators conclude that “due to the high level of treatment adherence already from baseline, no effects of a motivational interview support program could be demonstrated.”
Schreiber K, Kant M, Pfleger C, et al. High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis – results from a 24-month, multicenter, open-label Danish study. Patient Prefer Adherence. 2018 Jun 29;12:1139-1150. doi: 10.2147/PPA.S166278.